JP2025060836A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2025060836A5 JP2025060836A5 JP2024228411A JP2024228411A JP2025060836A5 JP 2025060836 A5 JP2025060836 A5 JP 2025060836A5 JP 2024228411 A JP2024228411 A JP 2024228411A JP 2024228411 A JP2024228411 A JP 2024228411A JP 2025060836 A5 JP2025060836 A5 JP 2025060836A5
- Authority
- JP
- Japan
- Prior art keywords
- chain
- polypeptide
- domain
- clostridial neurotoxin
- pain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024228411A JP2025060836A (ja) | 2021-03-30 | 2024-12-25 | 疼痛及び炎症性障害の処置 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023559998A JP7659653B2 (ja) | 2021-03-30 | 2021-03-30 | 疼痛及び炎症性障害の処置 |
| PCT/GB2021/050783 WO2022208039A1 (en) | 2021-03-30 | 2021-03-30 | Catalytically inactive clostridial neurotoxins for the treatment of pain & inflammatory disorders |
| JP2024228411A JP2025060836A (ja) | 2021-03-30 | 2024-12-25 | 疼痛及び炎症性障害の処置 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023559998A Division JP7659653B2 (ja) | 2021-03-30 | 2021-03-30 | 疼痛及び炎症性障害の処置 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025060836A JP2025060836A (ja) | 2025-04-10 |
| JP2025060836A5 true JP2025060836A5 (https=) | 2025-06-13 |
Family
ID=75396825
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023559998A Active JP7659653B2 (ja) | 2021-03-30 | 2021-03-30 | 疼痛及び炎症性障害の処置 |
| JP2024228411A Pending JP2025060836A (ja) | 2021-03-30 | 2024-12-25 | 疼痛及び炎症性障害の処置 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023559998A Active JP7659653B2 (ja) | 2021-03-30 | 2021-03-30 | 疼痛及び炎症性障害の処置 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250066755A1 (https=) |
| EP (1) | EP4297773A1 (https=) |
| JP (2) | JP7659653B2 (https=) |
| KR (2) | KR20230155007A (https=) |
| CN (2) | CN117396217A (https=) |
| AU (2) | AU2021438810B2 (https=) |
| BR (1) | BR112023018473A2 (https=) |
| CA (1) | CA3211472A1 (https=) |
| TW (1) | TW202304502A (https=) |
| WO (1) | WO2022208039A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023089343A1 (en) * | 2021-11-22 | 2023-05-25 | Ipsen Biopharm Limited | Treatment of pain |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| IL99552A0 (en) | 1990-09-28 | 1992-08-18 | Ixsys Inc | Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof |
| AU3658093A (en) | 1992-02-10 | 1993-09-03 | Seragen, Inc. | Desensitization to specific allergens |
| GB9305735D0 (en) | 1993-03-19 | 1993-05-05 | North John R | Novel agent for controlling cell activity |
| GB9508204D0 (en) | 1995-04-21 | 1995-06-07 | Speywood Lab Ltd | A novel agent able to modify peripheral afferent function |
| GB9617671D0 (en) | 1996-08-23 | 1996-10-02 | Microbiological Res Authority | Recombinant toxin fragments |
| US7192596B2 (en) | 1996-08-23 | 2007-03-20 | The Health Protection Agency Ipsen Limited | Recombinant toxin fragments |
| GB9721189D0 (en) | 1997-10-08 | 1997-12-03 | Speywood Lab The Limited | Analgesic conjugates |
| DK1084146T3 (da) | 1998-05-13 | 2003-02-03 | Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh | Hybridprotein til inhibering af degranuleringen af mastocyter og anvendelse deraf |
| ES2205849T3 (es) | 1998-07-22 | 2004-05-01 | Osprey Pharmaceuticals Limited | Conjugados para tratar alteraciones inflamatorias y asociadas con daños tisulares. |
| GB9818548D0 (en) | 1998-08-25 | 1998-10-21 | Microbiological Res Authority | Treatment of mucas hypersecretion |
| US6776990B2 (en) | 1999-04-08 | 2004-08-17 | Allergan, Inc. | Methods and compositions for the treatment of pancreatitis |
| US6358697B2 (en) | 1999-04-21 | 2002-03-19 | Children's Hospital Medical Center | Intracellular pharmaceutical targeting |
| HK1046020B (en) | 1999-08-25 | 2007-05-11 | Allergan, Inc. | Activatable recombinant neurotoxins |
| GB9922554D0 (en) | 1999-09-23 | 1999-11-24 | Microbiological Res Authority | Inhibition of secretion from non-neuronal cells |
| US7172764B2 (en) * | 2003-11-17 | 2007-02-06 | Allergan, Inc. | Rescue agents for treating botulinum toxin intoxications |
| DE102004043009A1 (de) | 2004-09-06 | 2006-03-23 | Toxogen Gmbh | Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen |
| PL1830872T3 (pl) | 2004-12-01 | 2011-09-30 | Sec Dep For Health | Białka fuzyjne |
| DE102005019302A1 (de) | 2005-04-26 | 2006-11-16 | Toxogen Gmbh | Carrier zum Targeting von Nervenzellen |
| ES2369558T3 (es) | 2005-09-19 | 2011-12-01 | Allergan, Inc. | Toxinas clostridiales y toxinas clostridiales activables. |
| AU2007272515B2 (en) | 2006-07-11 | 2013-09-26 | Allergan, Inc. | Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells |
| JP2009543558A (ja) | 2006-07-11 | 2009-12-10 | アラーガン、インコーポレイテッド | 増強した転位置能力および増強したターゲティング活性を有する改変クロストリジウム毒素 |
| SG10201606666XA (en) | 2012-05-30 | 2016-09-29 | Harvard College | Engineered Botulinum Neurotoxin |
| GB201312317D0 (en) | 2013-07-09 | 2013-08-21 | Syntaxin Ltd | Cationic neurotoxins |
| CN107108703B (zh) | 2015-01-09 | 2022-09-23 | 益普生生物创新有限公司 | 阳离子神经毒素 |
| PT3274364T (pt) | 2015-03-26 | 2021-11-05 | Harvard College | Neurotoxina botulínica manipulada |
| GB201607901D0 (en) | 2016-05-05 | 2016-06-22 | Ipsen Biopharm Ltd | Chimeric neurotoxins |
| EP3481852B1 (en) * | 2016-07-08 | 2022-12-07 | Children's Medical Center Corporation | A novel botulinum neurotoxin and its derivatives |
| UA128185C2 (uk) | 2018-01-29 | 2024-05-01 | Іпсен Біофарм Лімітед | Ботулінічний нейротоксин, який розщеплює ненейронний snare |
| GB201815817D0 (en) | 2018-09-28 | 2018-11-14 | Ispen Biopharm Ltd | Clostridial neurotoxins comprising and exogenous activation loop |
| WO2020219358A2 (en) * | 2019-04-17 | 2020-10-29 | Children's Medical Center Corporation | Catalytically inactive botulinum neurotoxin-like toxins and uses thereof |
| GB201914034D0 (en) * | 2019-09-30 | 2019-11-13 | Ipsen Biopharm Ltd | Treatment of neurological disorders |
-
2021
- 2021-03-30 JP JP2023559998A patent/JP7659653B2/ja active Active
- 2021-03-30 EP EP21716841.8A patent/EP4297773A1/en active Pending
- 2021-03-30 KR KR1020237035244A patent/KR20230155007A/ko not_active Ceased
- 2021-03-30 US US18/552,457 patent/US20250066755A1/en active Pending
- 2021-03-30 BR BR112023018473A patent/BR112023018473A2/pt unknown
- 2021-03-30 WO PCT/GB2021/050783 patent/WO2022208039A1/en not_active Ceased
- 2021-03-30 CA CA3211472A patent/CA3211472A1/en active Pending
- 2021-03-30 AU AU2021438810A patent/AU2021438810B2/en active Active
- 2021-03-30 CN CN202180098695.XA patent/CN117396217A/zh active Pending
- 2021-03-30 KR KR1020257013523A patent/KR20250060320A/ko active Pending
-
2022
- 2022-03-30 CN CN202280038084.0A patent/CN117396218A/zh active Pending
- 2022-03-30 TW TW111112192A patent/TW202304502A/zh unknown
-
2024
- 2024-10-07 AU AU2024227147A patent/AU2024227147A1/en active Pending
- 2024-12-25 JP JP2024228411A patent/JP2025060836A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007526330A5 (https=) | ||
| JP2020143164A5 (https=) | ||
| JPWO2019157224A5 (https=) | ||
| JP2025060836A5 (https=) | ||
| US20220153813A1 (en) | Method for promoting wound healing | |
| JP2009545313A5 (https=) | ||
| JP2005506340A5 (https=) | ||
| JP2008500373A5 (https=) | ||
| JP2003532742A (ja) | 神経損傷の修復 | |
| US10287583B2 (en) | Oligonucleotide decoys for the treatment of pain | |
| RU2002130203A (ru) | Пептидные конъюгаты для доставки лекарственного средства | |
| JP2024169509A (ja) | ファーバー病を治療するための組成物及び方法 | |
| JPWO2021116462A5 (https=) | ||
| CA2342770A1 (en) | Ly6h gene | |
| WO2001032196A1 (de) | Secretinfragmente zur behandlung von autismus | |
| JPWO2022208091A5 (https=) | ||
| CN103501794A (zh) | 脑靶向性功能性核酸及其利用 | |
| RU2023127652A (ru) | Каталитически неактивные клостридиальные нейротоксины для лечения боли и воспалительных заболеваний | |
| US10160791B2 (en) | Protamine in treatment of neuronal injuries | |
| JPWO2021229076A5 (https=) | ||
| JP2021518392A5 (https=) | ||
| EP3586867A2 (en) | Placenta growth factor in treating duchenne muscular dystrophy | |
| Hayashi et al. | Attenuation of glial scar formation in the injured rat brain by heparin oligosaccharides | |
| JP2005508875A5 (https=) | ||
| RU2785401C2 (ru) | Направленная регенерация переломанной кости посредством стимуляции рецептора паратиреоидного гормона |